Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.46 |
| ▸ | FNTB | P49356 | 10/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860941 | 0.87 | FNTA (0.47) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5861387 | 0.85 | DPP4 (0.37) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5862802 | 0.83 | FNTA (0.44) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5860957 | 0.79 | FNTA (0.46) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5862857 | 0.78 | FNTA (0.45) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5862889 | 0.78 | FNTA (0.45) | FNTAFNTBSLC6A4SLC6A2KCNH2 | |
| SCHEMBL5862851 | 0.76 | FNTA (0.44) | FNTAFNTB | |
| SCHEMBL5860858 | 0.76 | FNTA (0.54) | FNTAFNTB | |
| SCHEMBL5862162 | 0.76 | FNTA (0.60) | FNTAFNTB | |
| SCHEMBL5862248 | 0.76 | FNTA (0.54) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053223-B2 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040181068-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181068-A1 | Inhibitors of farnesyl protein transferase | FNTA, FNTB, ACAT2 | FNTA 1/4885FNTB 2/4885SLC6A4 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.